{"id":"W2014431621","doi":"10.3899/jrheum.130371","title":"Treatment of Relapsing Polychondritis with Tocilizumab","year":2013,"lang":"en","type":"letter","venue":"The Journal of Rheumatology","topic":"Otitis Media and Relapsing Polychondritis","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical","keywords":"Relapsing polychondritis; Chondritis; Medicine; Tocilizumab; Tenosynovitis; Cyclophosphamide; Chondropathy; Synovitis; Refractory (planetary science); Etanercept; Episcleritis; Surgery; Scleritis; Internal medicine; Dermatology; Arthritis; Rheumatoid arthritis; Chemotherapy; Immunology; Osteoarthritis; Pathology; Uveitis","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001162883,0.0003791229,0.001746422,0.000368138,0.00008197714,0.00001344712,0.000271274,0.0007798126,0.000383427],"category_scores_gemma":[0.00007970334,0.0001924079,0.000356312,0.0001666708,0.0006470989,0.00006985325,0.00002157095,0.001470168,0.00004627236],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000182301,"about_ca_system_score_gemma":0.0005346883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006824669,"about_ca_topic_score_gemma":0.00003650052,"domain_scores_codex":[0.997486,0.0002905196,0.001049699,0.0001714823,0.0005558135,0.0004464957],"domain_scores_gemma":[0.9969192,0.0005961437,0.001476821,0.0005335056,0.0003520614,0.0001222742],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005143119,0.0001524891,0.005411171,0.0002938956,0.001079064,0.001619974,0.001088098,9.104276e-7,0.0001802272,0.000020006,0.9851233,0.004516547],"study_design_scores_gemma":[0.006324503,0.008001422,0.0002018846,0.003482846,0.001664917,0.3626767,0.0002801039,0.000006183958,0.0002847459,0.0001376182,0.6166886,0.0002505532],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.2118253,0.02171059,0.0001784543,0.7452621,0.01838828,0.0007404732,0.00002494187,0.00003234243,0.001837456],"genre_scores_gemma":[0.1952542,0.225355,0.01669735,0.2227816,0.004508633,0.00008754687,0.0002855976,0.001176946,0.3338532],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.5224805,"threshold_uncertainty_score":0.7846165,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01322505670049788,"score_gpt":0.2448052124519433,"score_spread":0.2315801557514455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}